PLBY reports Q1 2026 earnings on Monday, May 11 — and the week's clearest tension is a stock that has climbed 14% over the past month while every executive with a Form 4 has been heading for the exit.
The insider selling is the standout angle here. CEO Ben Kohn sold shares on April 24. General Counsel Christopher Riley sold on April 24, again on May 4, and again on May 5 — offloading over 181,000 shares across those two sessions alone at prices between $1.75 and $1.78. CFO Marc Crossman sold 104,000 shares in late March at $1.66. The net 90-day insider figure runs to roughly 313,000 shares sold, worth around $543,000 in aggregate. These aren't transformative sums, but the pattern matters: the CEO, CFO, and general counsel have all sold into a rally that lifted the stock to its best levels of the recent recovery. None of the recent trades carries a high significance score, and these may partly reflect routine vesting-related disposals, but the direction of insider flow is uniformly one-way.
Options positioning reinforces the bullish tilt visible in price — which makes the insider selling all the more striking as a counterweight. The put/call ratio has collapsed to 0.13, well below its 20-day average of 0.22. That is close to the most call-heavy reading of the past year; the 52-week low is 0.008. The z-score of -0.84 confirms that options traders are skewed meaningfully toward upside bets. Borrow conditions add no friction to the picture: cost to borrow is just 0.64%, down sharply from the 1.5% range seen at the start of April, and availability in the lending market is ample. Short interest barely registers at 1.4% of the free float, essentially flat on the week and down 3% over the past month. There is no short-side pressure building here.
Momentum scores give the bulls something to point at. The EPS momentum reading ranks in the 91st percentile over 90 days and the 84th percentile over 30 days — suggesting estimate revisions have been running hot. The stock's P/E, at roughly 13x, is not stretched on a trailing basis, and EV/EBITDA has edged down slightly over the past month to around 11.5x. The mean analyst price target of $2.92 implies roughly 62% upside to Friday's $1.80 close, though that figure warrants a caveat: the most recent change on record is a Lucid Capital Markets initiation from July 2025, and the prior actions from Jefferies and Chardan are from 2024. The Street coverage is thin and the data is stale. Treat the target as directional rather than precise.
Institutional ownership tells its own story of concentrated, patient holders rather than active-manager rotation. Fortress holds 14.4% of shares, Rizvi Traverse 12.5%, and Byborg Enterprises just under 13%. Together those three names account for nearly 40% of shares outstanding — a float that leaves very little room for broad institutional momentum to develop. Among more active names, CRCM added over 2.2 million shares in Q4 last year, and Vanguard added 658,000 in Q1 2026. The ORTEX short score of 32 is unexceptional, sitting in the 55th percentile, consistent with a name that has no real short-side story at current positioning levels.
The last earnings call in mid-March produced a 4% one-day gain and a 6.5% five-day move — modest by small-cap standards but positive. That result sets a soft baseline for Monday's Q1 print. What to watch is whether the company can demonstrate licensing and brand revenue momentum sufficient to justify the EPS estimate acceleration that the factor scores imply, and whether the insider selling cadence slows or continues after the report.
See the live data behind this article on ORTEX.
Open PLBY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
